Tafamidis Meglumine Soft not checked

Qilu Pharmaceutical

FollowEvery change as it happens, and a Monday email
Next date
Phase 4 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Transthyretin Amyloid Polyneuropathy
Main trialPhase 4
“The purpose of this study is to evaluate the efficacy and safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients with Transthyretin Amyloid Polyneuropathy”In the company’s words, NCT06940336 on ClinicalTrials.gov

Other drugs for Transthyretin Amyloid Polyneuropathy

All 3 drugs for Transthyretin Amyloid Polyneuropathy

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 4Recruiting Jan 2028 To Evaluate the Efficacy and Safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients With Transthyretin Amyloid Polyneuropathy
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Tafamidis Meglumine Soft

Following is part of Solo: you see every change to Tafamidis Meglumine Soft the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in